title: Acceleration of wound healing in traumatic ulcers by absorbable collagen sponge containing recombinant basic fibroblast growth factor.
abstract: The objective of this study was to examine the safety and efficacy of topical application of recombinant basic fibroblast growth factor loaded on a kind of absorbable collagen sponge (rbFGF/ACS) in patients with chronic traumatic ulcers. This double-blind controlled trial included 58 patients with chronic traumatic ulcers. The patients were randomized into two groups. After debridement, the wounds were covered with rbFGF/ACS and then bound up with sterile gauze in the rbFGF/ACS group (n = 30), or bound up with petrolatum sterile gauze in the placebo group (n = 28). The complete closure of the wounds was assessed by photography. The wounds that failed to heal were defined as incomplete healing after 3 weeks. Compared with the placebo group, rbFGF/ACS significantly increased the incidence of complete wound closure by 68% (90.0% versus 53.6%, P = 0.0019) after 3 weeks and shortened the time to achieve complete wound closure by 24% (10.6 days versus 13.9 days, P = 0.0171). There was no difference in side effects between the two groups. rbFGF/ACS significantly increased the incidence of complete wound closure, shortened the complete healing time and improved the healing quality of chronic traumatic ulcers. The safety profile in the rbFGF/ACS group was similar to that in placebo group.
authors.affiliation: College of Pharmacy, Jinan University, Guangzhou 510632, People's Republic of China. zhzgg@tom.com
authors.forename: Chengcan
authors.initials: C
authors.lastname: Yao
authors.forename: Ping
authors.initials: P
authors.lastname: Yao
authors.forename: Hao
authors.initials: H
authors.lastname: Wu
authors.forename: Zhengang
authors.initials: Z
authors.lastname: Zha
mesh_terms: D000042:Absorption; D000328:Adult; D001458:Bandages; D003094:Collagen / Q000737:chemistry*; D004311:Double-Blind Method; D004337:Drug Carriers / Q000737:chemistry*; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D008297:Male; D012883:Skin Ulcer / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D004337:Drug Carriers; D016222:Fibroblast Growth Factor 2; D003094:Collagen